Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma, Renal Cell × Nephrectomy × Clear all

Status

Sponsor Class

OTHER 12 NIH 2 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

pembrolizumab 70 Nivolumab 54 Sunitinib 45 Sorafenib 31 Everolimus 30 pazopanib 25 cabozantinib 22 Axitinib 22 Ipilimumab 21 Bevacizumab 19 belzutifan 17 atezolizumab 16 lenvatinib 13 avelumab 10 Paclitaxel 9 temsirolimus 8 Docetaxel 8 Cyclophosphamide 8 Interferon alpha-2 7 fludarabine 6 durvalumab 6 tivozanib 5 spartalizumab 5 aldesleukin 5 Ramucirumab 5 Interleukin-2 5 Cetuximab 5 cemiplimab 4 Interferon-alpha 4 Carboplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04309617 2021-05-19

Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy

Pfizer

618 enrolled 33 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡